Skip to main content
SpringerLink
Log in

Detecting α-synuclein seeds in serum to diagnose synucleinopathies

  • Research Briefing
  • Published:

From Nature Medicine

View current issue Submit your manuscript

α-Synuclein seeds have been identified in various tissues in patients with synucleinopathies. We have developed real-time quaking-induced conversion combined with immunoprecipitation, a method that enables the detection of α-synuclein seeds from the serum of patients with synucleinopathies. This method can lay the foundation for the biological diagnosis of synucleinopathies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Structural differences between serum α-synuclein seeds obtained with IP/RT-QuIC.

References

  1. Hawkes, C. H., Tredici, K. D. & Braak, H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33, 599–614 (2007). An article on the ‘dual-hit’ hypothesis that the initial events of sporadic PD involve access to the brain via the stomach and nose.

  2. Lohmann, S. et al. Oral and intravenous transmission of α-synuclein fibrils to mice. Acta. Neuropathol. 138, 515–533 (2019). This paper discusses the blood pathway of α-synuclein spread.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chang, C. W., Yang, S. Y., Yang, C. C., Chang, C. W. & Wu, Y. R. Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson’s disease. Front. Neurol. 10, 1388 (2019). This article discusses peripheric α-synuclein as a biomarker.

    Article  PubMed  Google Scholar 

  4. Zubelzu, M., Morera-Herreras, T., Irastorza, G., Gómez-Esteban, J. C. & Murueta-Goyena, A. Plasma and serum alpha-synuclein as a biomarker in Parkinson’s disease: A meta-analysis. Parkinsonism Relat. Disord. 99, 107–115 (2022). An article showing that increased total plasma or serum α-synuclein levels in PD primarily occur in early phases of the disease.

    Article  CAS  PubMed  Google Scholar 

  5. Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812–818 (2016). An article on RT-QuIC analysis of cerebrospinal fluid for the early clinical assessment of patients with α-synucleinopathies.

  6. Shahnawaz, M. et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578, 273–277 (2020). An article on the potential development of a biochemical assay to discriminate between PD and MSA.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Okuzumi, A. et al. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat. Med. https://doi.org/10.1038/s41591-023-02358-9 (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Detecting α-synuclein seeds in serum to diagnose synucleinopathies. Nat Med 29, 1328–1329 (2023). https://doi.org/10.1038/s41591-023-02402-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02402-8

  • Springer Nature America, Inc.

Search

Navigation